Latest news with #ELISA
Mint
3 days ago
- Health
- Mint
India to introduce more advanced testing for imported blood products to reduce infection risk
New Delhi: The health ministry plans to mandate the use of a faster and more accurate method to test all imported blood products to maintain the highest safety standards and reduce the risk of infection from transfusions. The ministry intends to introduce nucleic acid testing (NAT) to improve the screening of imported blood products for antibodies of the human immunodeficiency virus (HIV), the hepatitis B virus, the hepatitis C virus and other impurities, an official aware of the matter said. The decision to shift to NAT has already been taken by the regulator, the Drug Controller General of India (DCGI), and the matter was discussed at the Drugs Technical Advisory Board meeting in April. The board is the highest statutory body responsible for advising the Central and state governments on technical matters related to the administration of the Drugs and Cosmetics Act, 1940. Also Read | Banking on blood: Health ministry frames guidelines to curb paid donations, improve efficacy of transfusions With the introduction of NAT, the conventional testing method known as ELISA, or enzyme-linked immunosorbent assay, will be done away with. ELISA, while a powerful tool, has several drawbacks, including the potential for false positive and negative results, apart from being time-consuming. The Department of Pharmaceuticals and the National Institute of Biologicals (NIB) in Noida had issued an alert in October after the NIB found three imported blood products—Berirab-P (used in rabies injections), Hepabig (to prevent hepatitis B virus infection) and Tetglob (used for tetanus treatment)—to be of sub-standard quality. When the Berirab-P and Hepabig samples were tested again at the National Institute of Virology in Pune using an advanced version of polymerase chain reaction, which is more sensitive than ELISA, they passed the test metrics. The set of Tetglob samples sent to a private laboratory that used ELISA were non-reactive. Safety standards Bharat Serums and Vaccines Ltd, now owned by Mankind Pharma, is the only company in the country that imports these lifesaving blood products. Imported blood products are used for the treatment of critically ill patients or those who are suffering thalassemia and other blood-related disorders. These products are tested at government laboratories to ensure they meet safety and quality standards. Also Read | India plans standard evaluation and quality protocols for HMPV' testing kits 'These are tested using conventional methods, but now the plan is to amend the rules to allow an advanced version of testing in line with international practices," the official said. 'NIB also proposed that an amendment may be considered to test blood products by NAT." Queries sent to the health ministry, the Department of Pharmaceuticals and the Mankind Pharma spokesperson remained unanswered till press time. 'NAT testing gives accurate and quick results and nowadays it is highly used. NAT testing is used for tuberculosis and NAT testing was modified during the covid-19 pandemic to detect the coronavirus," a scientist from the Indian Council of Medical Research said, requesting anonymity. 'The ELISA test may sometimes give false results if the viral load in the sample is low. However, PCR and NAT give accurate results even if the viral load is low." Also Read | ICMR and CDSCO develop framework for validation of pathogen identification and antimicrobial susceptibility testing According to an assessment by the National Blood Transfusion Council, the apex policymaking body for issues pertaining to blood and plasma, the clinical requirement of blood in the country is about 14.5 million units per year. The volume of each unit of blood is about 450 ml. In India, the import, manufacture, distribution and sale of drugs, cosmetics and notified medical devices are regulated by the Drugs and Cosmetics Act and the Drugs and Cosmetics Rules, 1945.
Yahoo
3 days ago
- Business
- Yahoo
Charles River Laboratories International, Inc. (CRL): A Bull Case Theory
We came across a bullish thesis on Charles River Laboratories International, Inc. (CRL) on scuttleblurb's Substack. In this article, we will summarize the bulls' thesis on CRL. Charles River Laboratories International, Inc. (CRL)'s share was trading at $136.25 as of 28th May. CRL's trailing and forward P/E were 25.07 and 14.41 respectively according to Yahoo Finance. A technician in a lab inspecting an ELISA test kit for use in biopharmaceutical diagnostics. Life sciences companies produce tangible tools like assays, bioreactors, and chromatography columns used across three key drug development phases: preclinical, clinical, and manufacturing. The preclinical phase, often split into discovery and regulatory safety testing, involves identifying and optimizing drug candidates through high-throughput screening and ADME-Tox tests, assessing absorption, distribution, metabolism, excretion, and toxicity. Charles River plays a significant role here by supplying cells and animals for testing, running screenings, and conducting ADME evaluations, although early discovery is mostly handled in-house due to its exploratory nature. As drug candidates progress, testing becomes more regulated, and outsourcing rises, particularly for Safety Assessment, which focuses on toxicity testing using larger mammals under strict Good Laboratory Practices (GLP). Charles River excels at these structured studies, which form about 60% of tox testing and require rigorous documentation and quality assurance. After successful safety testing, drugs enter clinical trials where clinical CROs lead, but Charles River remains involved through its Microbial Solutions and Biologics Testing divisions, ensuring drugs are free from microbial contamination and validating biologics' purity, potency, and safety. Despite initial attempts to enter drug manufacturing (CDMO) through acquisitions, Charles River exited a crowded small molecule space but reentered more strategically with acquisitions in cell and gene therapy manufacturing, aligning better with its biologics testing expertise. This focused approach positions Charles River as a critical and growing player in supporting biopharma through complex preclinical safety testing and manufacturing for cutting-edge therapies. For a comprehensive analysis of another standout stock in the healthcare industry, be sure to check out our article on Danaher Corporation (DHR), wherein we summarized a bullish thesis by Best Anchor Stocks on Substack. Charles River Laboratories International, Inc. (CRL) is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 39 hedge fund portfolios held CRL at the end of the first quarter which was 45 in the previous quarter. While we acknowledge the risk and potential of CRL as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than CRL but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. This article was originally published at Insider Monkey.
Business Upturn
4 days ago
- Business
- Business Upturn
Free Antibody Validation: Boster Bio Launches New Service to Advance Research Reproducibility
Pleasanton, May 29, 2025 (GLOBE NEWSWIRE) — Pleasanton, California – With Boster Bio's latest promotion, scientists globally enjoy free access to antibody validation to boost research accuracy. Boster Biological Technology, a leading provider of high-quality antibodies and ELISA kits, has announced a new promotion offering free antibody validation for its PicoBand antibody line. This initiative is designed to help scientists worldwide enhance research reliability by eliminating guesswork in antibody selection, allowing researchers to verify antibody specificity before purchase. The PicoBand product line includes ultra-sensitive antibodies optimized for Western blotting (WB), immunohistochemistry (IHC), flow cytometry, and other key applications. Through this free Picoband antibody validation program, researchers can receive validation data for their antibody of interest, improving reproducibility in life sciences research. 'For decades, scientists have been forced to gamble on antibodies that might not work, leading to a waste of time, money, and resources. With our free PicoBand validation program, we're flipping the script. Not only can researchers now verify antibody performance before they commit, but submitting a request takes only two minutes and saves researchers days in lab work,' said CJ Xia, founder of Boster Bio. Antibodies are critical tools in biomedical research, but inconsistent quality and lack of validation have led to reproducibility challenges. Boster Bio's free antibody validation program addresses this issue by providing documented proof of antibody performance without expending time and resources in the lab. Each batch undergoes strict quality control and is presented in detailed datasheets with experimental results. Boster Bio's validation service addresses a longstanding industry issue—the inconsistent quality of antibodies. Researchers can choose from over 8,000 PicoBand antibodies, with the option to request validation on over 500 sample types, including human, mouse, rat, monkey, and zebrafish. Each antibody undergoes multi-application validation, covering WB, IHC, IF, ELISA, flow cytometry, and immunoprecipitation to ensure compatibility with diverse experimental needs. This initiative underscores Boster Bio's commitment to transparency, accountability, and reproducibility in life sciences research, reinforcing its position as an innovator in reliable antibody production. Unlike typical vendors, Boster Bio's no-strings-attached policy allows researchers to verify performance data upfront, eliminating guesswork and costly trial-and-error purchases. For more information, visit the website at Founded in 1993, Boster Biological Technology has built a reputation for high-affinity antibodies, ELISA kits, and protein analysis tools, products widely used globally in academic, pharmaceutical, and biotech research. Promoting the free antibody validation aligns with Boster Bio's mission to support the scientific community with dependable reagents, providing clients with antibody validation before purchase. For decades, scientists have been forced to gamble hundreds or thousands of dollars on antibodies that might not even work and had to rely on reputation, citations, and gut instinct to pick reagents, resulting in unreliable data, weeks of wasted time, and little support. 'At Boster Bio, our mission is to move the antibody industry into its next stage. We're not offering a free sample, but starting a movement. It's a fundamental rethinking of what it means to support scientific discovery. When vendors take responsibility for antibody performance upfront, scientists can focus on what matters most—discovery,' added Xia. This initiative underscores the company's commitment to transparency and reproducibility in life sciences. By providing free Picoband antibody validation, Boster Bio empowers labs to conduct experiments confidently, reducing wasted resources and accelerating discoveries. Scientists worldwide can leverage this program to access high-affinity, batch-consistent antibodies backed by documented proof of specificity. Specializing in antibodies, ELISA kits, and protein research tools, Boster Biological Technology is committed to delivering high-quality products. With the recent unveiling of its manifesto for antibody accountability, Boster Bio is offering free antibody validation services to meet the client's experiment settings. More than just a promotion, this program is designed to raise industry standards, redefining how antibodies are evaluated and adopted to ensure continued scientific rigor and customer success. About the Company: Boster Biological Technology is a global leader in antibody production and immunoassay solutions, serving academic, pharmaceutical, and biotech researchers. Based in Pleasanton, CA, the company contributes significantly to accelerating scientific discovery through innovative reagents and exceptional service. Boster Bio is committed to transparency and reproducibility, offering free antibody validation in WB, IHC, IF, flow cytometry, IP, and ELISA, ensuring researchers receive fully characterized reagents. ### For more information about Boster Biological Technology, contact the company here: Boster Biological TechnologyCJ Xia(888) 466-3604 [email protected] 3942 Valley Ave, Pleasanton, CA 94566, USA
Yahoo
4 days ago
- Business
- Yahoo
Free Antibody Validation: Boster Bio Launches New Service to Advance Research Reproducibility
Pleasanton, May 29, 2025 (GLOBE NEWSWIRE) -- Pleasanton, California - With Boster Bio's latest promotion, scientists globally enjoy free access to antibody validation to boost research accuracy. Boster Biological Technology, a leading provider of high-quality antibodies and ELISA kits, has announced a new promotion offering for its PicoBand antibody line. This initiative is designed to help scientists worldwide enhance research reliability by eliminating guesswork in antibody selection, allowing researchers to verify antibody specificity before purchase. The PicoBand product line includes ultra-sensitive antibodies optimized for Western blotting (WB), immunohistochemistry (IHC), flow cytometry, and other key applications. Through this free Picoband antibody validation program, researchers can receive validation data for their antibody of interest, improving reproducibility in life sciences research. "For decades, scientists have been forced to gamble on antibodies that might not work, leading to a waste of time, money, and resources. With our free PicoBand validation program, we're flipping the script. Not only can researchers now verify antibody performance before they commit, but submitting a request takes only two minutes and saves researchers days in lab work," said CJ Xia, founder of Boster Bio. Antibodies are critical tools in biomedical research, but inconsistent quality and lack of validation have led to reproducibility challenges. Boster Bio's free antibody validation program addresses this issue by providing documented proof of antibody performance without expending time and resources in the lab. Each batch undergoes strict quality control and is presented in detailed datasheets with experimental results. Boster Bio's validation service addresses a longstanding industry issue—the inconsistent quality of antibodies. Researchers can choose from over 8,000 PicoBand antibodies, with the option to request validation on over 500 sample types, including human, mouse, rat, monkey, and zebrafish. Each antibody undergoes multi-application validation, covering WB, IHC, IF, ELISA, flow cytometry, and immunoprecipitation to ensure compatibility with diverse experimental needs. This initiative underscores Boster Bio's commitment to transparency, accountability, and reproducibility in life sciences research, reinforcing its position as an innovator in reliable antibody production. Unlike typical vendors, Boster Bio's no-strings-attached policy allows researchers to verify performance data upfront, eliminating guesswork and costly trial-and-error purchases. For more information, visit the website at Founded in 1993, Boster Biological Technology has built a reputation for high-affinity antibodies, ELISA kits, and protein analysis tools, products widely used globally in academic, pharmaceutical, and biotech research. Promoting the free antibody validation aligns with Boster Bio's mission to support the scientific community with dependable reagents, providing clients with antibody validation before purchase. For decades, scientists have been forced to gamble hundreds or thousands of dollars on antibodies that might not even work and had to rely on reputation, citations, and gut instinct to pick reagents, resulting in unreliable data, weeks of wasted time, and little support. "At Boster Bio, our mission is to move the antibody industry into its next stage. We're not offering a free sample, but starting a movement. It's a fundamental rethinking of what it means to support scientific discovery. When vendors take responsibility for antibody performance upfront, scientists can focus on what matters most—discovery," added Xia. This initiative underscores the company's commitment to transparency and reproducibility in life sciences. By providing free Picoband antibody validation, Boster Bio empowers labs to conduct experiments confidently, reducing wasted resources and accelerating discoveries. Scientists worldwide can leverage this program to access high-affinity, batch-consistent antibodies backed by documented proof of specificity. Specializing in antibodies, ELISA kits, and protein research tools, Boster Biological Technology is committed to delivering high-quality products. With the recent unveiling of its manifesto for antibody accountability, Boster Bio is offering free antibody validation services to meet the client's experiment settings. More than just a promotion, this program is designed to raise industry standards, redefining how antibodies are evaluated and adopted to ensure continued scientific rigor and customer success. About the Company: Boster Biological Technology is a global leader in antibody production and immunoassay solutions, serving academic, pharmaceutical, and biotech researchers. Based in Pleasanton, CA, the company contributes significantly to accelerating scientific discovery through innovative reagents and exceptional service. Boster Bio is committed to transparency and reproducibility, offering free antibody validation in WB, IHC, IF, flow cytometry, IP, and ELISA, ensuring researchers receive fully characterized reagents. ### For more information about Boster Biological Technology, contact the company here:Boster Biological TechnologyCJ Xia(888) 466-3604sales@ Valley Ave, Pleasanton, CA 94566, USA CONTACT: CJ XiaError while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
4 days ago
- Business
- Yahoo
Free Antibody Validation: Boster Bio Launches New Service to Advance Research Reproducibility
Pleasanton, May 29, 2025 (GLOBE NEWSWIRE) -- Pleasanton, California - With Boster Bio's latest promotion, scientists globally enjoy free access to antibody validation to boost research accuracy. Boster Biological Technology, a leading provider of high-quality antibodies and ELISA kits, has announced a new promotion offering for its PicoBand antibody line. This initiative is designed to help scientists worldwide enhance research reliability by eliminating guesswork in antibody selection, allowing researchers to verify antibody specificity before purchase. The PicoBand product line includes ultra-sensitive antibodies optimized for Western blotting (WB), immunohistochemistry (IHC), flow cytometry, and other key applications. Through this free Picoband antibody validation program, researchers can receive validation data for their antibody of interest, improving reproducibility in life sciences research. "For decades, scientists have been forced to gamble on antibodies that might not work, leading to a waste of time, money, and resources. With our free PicoBand validation program, we're flipping the script. Not only can researchers now verify antibody performance before they commit, but submitting a request takes only two minutes and saves researchers days in lab work," said CJ Xia, founder of Boster Bio. Antibodies are critical tools in biomedical research, but inconsistent quality and lack of validation have led to reproducibility challenges. Boster Bio's free antibody validation program addresses this issue by providing documented proof of antibody performance without expending time and resources in the lab. Each batch undergoes strict quality control and is presented in detailed datasheets with experimental results. Boster Bio's validation service addresses a longstanding industry issue—the inconsistent quality of antibodies. Researchers can choose from over 8,000 PicoBand antibodies, with the option to request validation on over 500 sample types, including human, mouse, rat, monkey, and zebrafish. Each antibody undergoes multi-application validation, covering WB, IHC, IF, ELISA, flow cytometry, and immunoprecipitation to ensure compatibility with diverse experimental needs. This initiative underscores Boster Bio's commitment to transparency, accountability, and reproducibility in life sciences research, reinforcing its position as an innovator in reliable antibody production. Unlike typical vendors, Boster Bio's no-strings-attached policy allows researchers to verify performance data upfront, eliminating guesswork and costly trial-and-error purchases. For more information, visit the website at Founded in 1993, Boster Biological Technology has built a reputation for high-affinity antibodies, ELISA kits, and protein analysis tools, products widely used globally in academic, pharmaceutical, and biotech research. Promoting the free antibody validation aligns with Boster Bio's mission to support the scientific community with dependable reagents, providing clients with antibody validation before purchase. For decades, scientists have been forced to gamble hundreds or thousands of dollars on antibodies that might not even work and had to rely on reputation, citations, and gut instinct to pick reagents, resulting in unreliable data, weeks of wasted time, and little support. "At Boster Bio, our mission is to move the antibody industry into its next stage. We're not offering a free sample, but starting a movement. It's a fundamental rethinking of what it means to support scientific discovery. When vendors take responsibility for antibody performance upfront, scientists can focus on what matters most—discovery," added Xia. This initiative underscores the company's commitment to transparency and reproducibility in life sciences. By providing free Picoband antibody validation, Boster Bio empowers labs to conduct experiments confidently, reducing wasted resources and accelerating discoveries. Scientists worldwide can leverage this program to access high-affinity, batch-consistent antibodies backed by documented proof of specificity. Specializing in antibodies, ELISA kits, and protein research tools, Boster Biological Technology is committed to delivering high-quality products. With the recent unveiling of its manifesto for antibody accountability, Boster Bio is offering free antibody validation services to meet the client's experiment settings. More than just a promotion, this program is designed to raise industry standards, redefining how antibodies are evaluated and adopted to ensure continued scientific rigor and customer success. About the Company: Boster Biological Technology is a global leader in antibody production and immunoassay solutions, serving academic, pharmaceutical, and biotech researchers. Based in Pleasanton, CA, the company contributes significantly to accelerating scientific discovery through innovative reagents and exceptional service. Boster Bio is committed to transparency and reproducibility, offering free antibody validation in WB, IHC, IF, flow cytometry, IP, and ELISA, ensuring researchers receive fully characterized reagents. ### For more information about Boster Biological Technology, contact the company here:Boster Biological TechnologyCJ Xia(888) 466-3604sales@ Valley Ave, Pleasanton, CA 94566, USA CONTACT: CJ Xia
